Trial and experimental group | Number of mice | 0, 2, 4 wpv b | 6-wpv b | 1-wpc c | 1-11 wpc c(80-dpc) | |
---|---|---|---|---|---|---|
Vaccination | Cytokine assay | Challenge | Larval recovery | Mortality | ||
(Trial I) | (3 times per group) | (No. a) | (No. a, d) | (No. a) | (No. a) | |
rBsc-PYP-1/FCA/PBS | 30 | rBsc-PYP-1 (FCA plus PBS) | 10 | 20 | 10 | 10 |
FCA/PBS | 30 | FCA plus PBS | 10 | 20 | 10 | 10 |
PBS | 30 | PBS | 10 | 20 | 10 | 10 |
Trial and experimental group | Number of mice | 0, 2, 4 wpv b | 5-wpv b | 6-wpv b | 1-wpc c | 1-12 wpc c (80-dpc) |
Vaccination | Challenge | Cytokine assay | Larval recovery | Mortality | ||
(Trial II) | (3 times per group) | (No. a ) | (No. a, e ) | (No. a, f ) | (No. a ) | |
rBsc-PYP-1/FCA/PBS | 30 | rBsc-PYP-1 (FCA plus PBS) | 20 | 10 | 10 | - |
FCA/PBS | 30 | FCA plus PBS | 20 | 10 | 10 | - |
PBS | 30 | PBS | 20 | 10 | 10 | - |